Table 3.
Unit costs and cycle costs
| Cost (US$) | 95% CI | Distribution | Source | |
|---|---|---|---|---|
| Unit costs | ||||
| Drug acquisition | ||||
| Niraparib | ||||
| Bottle of 30 100-mg capsules | 6584 | N/A | N/A | [31] |
| One 100-mg capsule | 219.47 | N/A | N/A | Calculation |
| Olaparib | ||||
| Pack of 120 150-mg tablets | 13,886 | N/A | N/A | [31] |
| One 150-mg tablet | 115.72 | N/A | N/A | Calculation |
| Rucaparib | ||||
| Pack of 120 300-mg tablets | 14,702 | N/A | N/A | [31] |
| One 300-mg tablet | 122.52 | N/A | N/A | Calculation |
| Drug administration | ||||
| Oral drugs | 0 | N/A | N/A | Assumption |
| Intravenous subsequent chemotherapy drugs | 143 | 93–204 | Gamma | [32] |
| Monitoring | ||||
| Outpatient visit | 78.09 | 50.54–111.55 | Gamma | [33, 34] |
| CT scan | 541.70 | 350.56–773.77 | Gamma | [33, 34] |
| Blood test | 15.23 | 9.85–21.75 | Gamma | [33, 34] |
| Adverse event | ||||
| Anaemia | 755.92 | 489.19–1079.76 | Gamma | [35] |
| Thrombocytopenia | 732.30 | 473.90–1046.02 | Gamma | [35] |
| Neutropenia | 867.98 | 561.71–1239.83 | Gamma | [35] |
| Fatigue | 0.00 | 0.00–0.00 | Gamma | [36] |
| Hypertension | 215.37 | 139.38–307.64 | Gamma | [35, 36] |
| Nausea | 678.24 | 438.92–968.80 | Gamma | [35] |
| Vomiting | 678.24 | 438.92–968.80 | Gamma | [35] |
| Terminal care | ||||
| Terminal care | 85,904 | 55,592–122,705 | Gamma | [37] |
| Cycle costs | ||||
| Drug acquisition | ||||
| Niraparib (200 mg QD) | 13,168 | N/A | N/A | Calculation |
| Olaparib (600 mg QD) | 13,886 | N/A | N/A | Calculation |
| Rucaparib (1200 mg QD) | 14,702 | N/A | N/A | Calculation |
| Monitoring | ||||
| gBRCAmut | ||||
| Niraparib | ||||
| PFD | 10,952 | N/A | N/A | Calculation |
| PD | 1539 | N/A | N/A | Calculation |
| RS | ||||
| PFD | 2772 | N/A | N/A | Calculation |
| PD | 833 | N/A | N/A | Calculation |
| Olaparib | ||||
| PFD | 10,906 | N/A | N/A | Calculation |
| PD | 1539 | N/A | N/A | Calculation |
| Rucaparib | ||||
| PFD | 8209 | N/A | N/A | Calculation |
| PD | 1428 | N/A | N/A | Calculation |
| Non-gBRCAmut | ||||
| Niraparib | ||||
| PFD | 7208 | N/A | N/A | Calculation |
| PD | 894 | N/A | N/A | Calculation |
| RS | ||||
| PFD | 3514 | N/A | N/A | Calculation |
| PD | 528 | N/A | N/A | Calculation |
| Olaparib | ||||
| PFD | 4817 | N/A | N/A | Calculation |
| PD | 662 | N/A | N/A | Calculation |
| Rucaparib | ||||
| PFD | 5090 | N/A | N/A | Calculation |
| PD | 992 | N/A | N/A | Calculation |
CI confidence interval, CT computed tomography, PD progressed disease, PFD progression-free disease, QD per day, RS routine surveillance